Agouron to buy certain rights to immune response AIDS drug

Article Abstract:

Agouron Pharmaceuticals Inc. said that it agreed to pay as much as $77 million to acquire certain rights to a controversial AIDS drug, Remune, that Immune Response Corp. has been developing over the past ten years. The drug is undergoing several human tests including a 2,500-patient study at more than 70 US medical centers. Remune was inspired by the late Jonas Salk, who thought that a deactivataed version of the AIDS virus might work in much the same way that the polio vaccine he developed in the 1950s worked.

Comment:

Agreed to pay as much as $77 mil to acquire certain rights to a controversial AIDS drug, Remune

Pharmaceutical Preparation Manufacturing, Antiinfective Preparations, Anti-infective agents, Immune Response Corp.

---

WellPoint set to buy Georgia medical firm

Article Abstract:

WellPoint Health Networks Inc. announced that it has reached an agreement to purchase Blue Cross' and Blue Shield's parent company, Cerulean Cos., for company stock worth $500 million. Cerulean is the owner of the largest health insurer in Georgia. The planned takeover would be the biggest in WellPoint's history. It would also be the company's first acquisition of another Blue-branded plan.

Comment:

To purchase Blue Cross' and Blue Shield's parent company, Cerulean Cos., for company stock worth $500 million

Health Care, Health Care and Social Assistance, Direct Health and Medical Insurance Carriers, Medical Care Insurance, Medical care, Health insurance, WellPoint Health Networks Inc., Cerulean Cos.

---

Warner-Lambert agrees to buy Agouron

Article Abstract:

Warner-Lambert Co. announced it will buy San Diego-based drug company Agouron Pharmaceuticals Inc. in a $2.1 billion stock deal. Agouron has AIDS and other drugs that can enhance the New Jersey firm's product pipeline. Merging the two cultures might be a challenge, though. And Warner-Lambert has no experience in the AIDS arena.

Comment:

To be acquired by Warner-Lambert for $2.1 billion in stock

Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Drugs, Mergers, acquisitions and divestments, Abstract, Warner-Lambert Co., WLA, AGPH

Similar abstracts:

• Abstracts: 3Com earnings, topping forecasts, suggest a rebound. Nortel agrees to acquire Bay Networks
• Abstracts: Cargill to buy grain assets from its rival. A big gamble on seeds, drugs gets riskier. An experiment in splicing together two CEOs
• Abstracts: Dunlap faces a fight over his severance pay. Sunbeam concedes 1997 statements may be off
• Abstracts: Boston Scientific to acquire Pfizer unit. Conservative Stryker joins the merger game in a big way. J & J agrees to buy DePuy for $3.5 billion
• Abstracts: United Rentals to acquire U.S. Rentals for stock valued at about $1 Billion United Video pulls its $2.8 billion bid for rival Gemstar

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.